The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. West Pharmaceutical Services's Revenue for the
three
months ended in Mar. 2026 was $845 Mil. West Pharmaceutical Services's average Accounts Receivable for the
three
months ended in Mar. 2026 was $630 Mil.
Hence, West Pharmaceutical Services's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.34.
West Pharmaceutical Services (NYSE:WST) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
West Pharmaceutical Services Receivables Turnover Related Terms
West Pharmaceutical Services Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
West Pharmaceutical Services Receivables Turnover Chart
WST vs RMD, MDLN, COO: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
West Pharmaceutical Services Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where West Pharmaceutical Services's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
West Pharmaceutical Services (WST) has a Receivables Turnover of 1.34 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on West Pharmaceutical Services and its competitors. According to the industry distribution chart, West Pharmaceutical Services ranks #428 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 52.7%.
Is West Pharmaceutical Services' Receivables Turnover too high?
West Pharmaceutical Services' current Receivables Turnover is 1.34. The Medical Devices & Instruments industry median Receivables Turnover is 5.53. West Pharmaceutical Services' value of 1.34 is 75.8% below this industry median. Based on the distribution chart, West Pharmaceutical Services ranks #428 out of 812 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, West Pharmaceutical Services has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' Receivables Turnover compare to RMD and MDLN?
According to the Medical Devices & Instruments industry distribution chart, West Pharmaceutical Services ranks #428 out of 812 companies for Receivables Turnover. This places West Pharmaceutical Services in the lower half of its industry. The industry median Receivables Turnover is 5.53. West Pharmaceutical Services' value of 1.34 is 75.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.53, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. West Pharmaceutical Services's current Receivables Turnover of 1.34 is 75.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on West Pharmaceutical Services and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. West Pharmaceutical Services's current Receivables Turnover is 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (WST) is currently considered Fairly Valued. The stock's GF Value™ is $362.09, compared to a current price of $359.54 — trading 0.7% below its estimated fair value. The current Receivables Turnover is 1.34 and 75.8% below the Medical Devices & Instruments industry median of 5.53. West Pharmaceutical Services' overall GF Score™ is 95/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For West Pharmaceutical Services (WST), the current Receivables Turnover is 1.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is West Pharmaceutical Services (WST) Overvalued in 2026?
Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued.
The current stock price of $359.54 is trading 0.7% below its estimated GF Value™ of $362.09.
GuruFocus considers West Pharmaceutical Services to be Fairly Valued.
Key valuation signals for WST:
Receivables Turnover: 1.34
GF Value™: $362.09 vs. price of $359.54 (0.7% below fair value)
Industry Position: 75.8% below the Medical Devices & Instruments median (#428 of 812)
No single metric tells the full story. See the WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
95GF Score
Get the complete analysis for WST
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WST has been successfully added to your 
